
Overview
Galderma Polska operates in dermatology, spanning injectable aesthetics, dermatological skincare and therapeutic dermatology. Galderma’s portfolio includes Nemluvio, a medicine discussed in connection with the treatment of atopic dermatitis.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
An unpredictable environment: navigating triggers in atopic dermatitis
Galderma
Fall Clinical 2026: Galderma presents new three-year Nemluvio® data
Galderma
Aesthetic treatments for menopause-related skin changes are gaining ground
Galderma
30 years of Restylane®: reshaping the aesthetics field through science-led innovation
Galderma
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio®
Galderma
EADV 2026: Galderma’s scientific presentations and activities
Galderma
Industry
Bank accounts
Registered as a VAT taxpayer on 2001-10-11. Active
05 1030 1508 0000 0005 0274 7002
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 18, 2012 | Merger registered |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Authorized Representatives
Manner of representation
Two members of the management board acting jointly are authorized to represent the company, submit declarations and sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Galderma Pharma S.A. | 186 | $25,121.56 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Nivea Polskasp. z o.o. | $230,652,184.83 | nivea.pl | ||
| Roche Diagnostics Polskasp. z o.o. | $199,208,461.57 | roche.pl | ||
| Servier Polska Servicessp. z o.o. | $157,143,144.15 | servier.pl | ||
| Gilead Sciences Polandsp. z o.o. | $150,844,944.19 | gilead.com | ||
| Magnapharm Polandsp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Dermaticsp. z o.o. | $33,423,317.64 | dermatic.pl | ||
| Consultronixsp. z o.o. | $29,089,133.20 | consultronix.pl | ||
| LR Health & Beauty Systemssp. z o.o. | $24,626,266.65 | lrworld.com | ||
| Ursapharm Polandsp. z o.o. | $16,296,973.60 | ursapharm.pl | ||
| Vitamed Pharmaceuticalssp. z o.o. | $14,515,124.01 | vitamed.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-02-28 | Name change ("galderma Polska" → Galderma Polska) | |
| 2020-03-27 | Address change (Łączyny 4, 02-820, Warszawa → Ul. Puławska 145, 02-715, Warszawa) | |
| 2012-07-06 | Share capital change (50,000.00 PLN → 93,000.00 PLN) | |
| 2001-10-09 | Entered in the register |
FAQ
Last updated: 2026-10-07